Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis
Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Arthritis Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13075-025-03607-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849343379373031424 |
|---|---|
| author | Marina G. Birck Jessica Boivin Laura Yan Nathalie Carrier Cristiano S. Moura Walter P. Maksymowych Gilles Boire Denis Choquette Luck Lukusa Michael Mallinson Linda Wilhelm Autumn Neville Sasha Bernatsky |
| author_facet | Marina G. Birck Jessica Boivin Laura Yan Nathalie Carrier Cristiano S. Moura Walter P. Maksymowych Gilles Boire Denis Choquette Luck Lukusa Michael Mallinson Linda Wilhelm Autumn Neville Sasha Bernatsky |
| author_sort | Marina G. Birck |
| collection | DOAJ |
| description | Abstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission. Results We studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2–12.1) in the ETA-B group and 14.5 months (95% CI 4.7–18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: P-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68–3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29–4.87). Conclusion We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O. Trial registration Not applicable. |
| format | Article |
| id | doaj-art-2c6b9f84b8c342238bcf29bdca062f8a |
| institution | Kabale University |
| issn | 1478-6362 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Arthritis Research & Therapy |
| spelling | doaj-art-2c6b9f84b8c342238bcf29bdca062f8a2025-08-20T03:43:01ZengBMCArthritis Research & Therapy1478-63622025-07-012711710.1186/s13075-025-03607-7Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysisMarina G. Birck0Jessica Boivin1Laura Yan2Nathalie Carrier3Cristiano S. Moura4Walter P. Maksymowych5Gilles Boire6Denis Choquette7Luck Lukusa8Michael Mallinson9Linda Wilhelm10Autumn Neville11Sasha Bernatsky12Research Institute of the McGill University Health CentreResearch Institute of the McGill University Health CentreMcGill UniversityCentre integré universitaire de santé et de services sociaux de l’Estrie– Centre hospitalier de Sherbrooke (CIUSSS de l’Estrie-CHUS)Research Institute of the McGill University Health CentreUniversity of AlbertaCentre integré universitaire de santé et de services sociaux de l’Estrie– Centre hospitalier de Sherbrooke (CIUSSS de l’Estrie-CHUS)Institut de Rhumatologie de Montréal, Centre hospitalier de l’Université de MontréalResearch Institute of the McGill University Health CentreCanadian Spondylitis Association, and Axial Spondyloarthritis International FederationCanadian Arthritis Patient AllianceResearch Institute of the McGill University Health CentreResearch Institute of the McGill University Health CentreAbstract Background We compared time to first remission and prevalence of sustained remission in participants with rheumatoid arthritis (RA) initiating etanercept biosimilar (ETA-B) or originator (ETA-O). Methods We studied etanercept-naive participants with RA from four Canadian prospective cohorts who initiated ETA-B or ETA-O (Jan/2015-May/2022). Disease remission was determined using disease activity scales. Sustained remission was defined as at least two consecutive visits in remission within the first 12 months of follow-up. Multivariate Cox regression was used to compare the probability of achieving remission between ETA-B and ETA-O, and multivariate logistic regression was used to assess sustained remission. Results We studied 150 participants with RA (ETA-B: 65.3%). Among 125 participants not in remission at baseline, the median time to first remission was 8.7 months (95% confidence intervals [CI] 5.2–12.1) in the ETA-B group and 14.5 months (95% CI 4.7–18.6) in the ETA-O group. Time to first remission was similar between the groups (log-rank test: P-value = 0.51). Multivariate Cox regression showed no clear difference in first remission between ETA-B and ETA-O (adjusted hazard ratio 1.52, 95% CI 0.68–3.39). Among 125 participants with at least 12 months of follow-up, the prevalence of sustained remission was 19.5% for ETA-B and 21.0% for ETA-O. In multivariate analysis, we did not detect a significant difference in sustained remission between ETA-B and ETA-O (adjusted odds ratio 1.14, 95% CI 0.29–4.87). Conclusion We did not detect clear differences in first remission and sustained remission between participants with RA initiating ETA-B or ETA-O. Trial registration Not applicable.https://doi.org/10.1186/s13075-025-03607-7Rheumatoid arthritisEtanerceptRemission inductionBiosimilar pharmaceuticals |
| spellingShingle | Marina G. Birck Jessica Boivin Laura Yan Nathalie Carrier Cristiano S. Moura Walter P. Maksymowych Gilles Boire Denis Choquette Luck Lukusa Michael Mallinson Linda Wilhelm Autumn Neville Sasha Bernatsky Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis Arthritis Research & Therapy Rheumatoid arthritis Etanercept Remission induction Biosimilar pharmaceuticals |
| title | Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis |
| title_full | Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis |
| title_fullStr | Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis |
| title_full_unstemmed | Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis |
| title_short | Disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis: an interim real-world analysis |
| title_sort | disease remission and sustained remission after etanercept biosimilar or originator initiation in rheumatoid arthritis an interim real world analysis |
| topic | Rheumatoid arthritis Etanercept Remission induction Biosimilar pharmaceuticals |
| url | https://doi.org/10.1186/s13075-025-03607-7 |
| work_keys_str_mv | AT marinagbirck diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT jessicaboivin diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT laurayan diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT nathaliecarrier diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT cristianosmoura diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT walterpmaksymowych diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT gillesboire diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT denischoquette diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT lucklukusa diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT michaelmallinson diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT lindawilhelm diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT autumnneville diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis AT sashabernatsky diseaseremissionandsustainedremissionafteretanerceptbiosimilarororiginatorinitiationinrheumatoidarthritisaninterimrealworldanalysis |